Clinical

Dataset Information

0

A Phase III Randomized Study of BBI608 and Best Supportive Care versus Placebo and Best Supportive Care in Patients with Pretreated Advanced Colorectal Carcinoma


ABSTRACT: Interventions: Group 1: Best supportive care plus BBI608. Best supportive care defined as those measures designed to provide palliation of symptoms and improve quality of life as much as possible. BBI608 will be self-administered by participants at 480mg (6 x 80mg tablets) orally twice daily (960mg total daily dose) in 28 day cycles. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and are, in the opinion of the investigator, continuing to derive benefit from protocol therapy. Patients will be asked to keep a diary of when they take the capsules and if they miss any doses to monitor adherance. Patients will also be asked to return any tablets which were not taken. Primary outcome(s): Overall survival (death from any cause)[Patient status updates will be sought every 2-4 weeks at clinic visit whilst on treatment and then every 8 weeks until death.] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial

DISEASE(S): Advanced (metastatic Or Locally Advanced) Colorectal Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2459551 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2143054 | ecrin-mdr-crc
| 2010537 | ecrin-mdr-crc
| 2222712 | ecrin-mdr-crc
| 2452710 | ecrin-mdr-crc
| 2111195 | ecrin-mdr-crc
| 2240059 | ecrin-mdr-crc
| S-EPMC6934749 | biostudies-literature
| S-EPMC3603584 | biostudies-literature
| S-EPMC5104888 | biostudies-literature
| S-EPMC10833516 | biostudies-literature